Streetbeat News

Partnerships

HUDI

Huadi International Group Co reported H1 2023 earnings per share (EPS) of $0.10, up from $0.00 YoY, and revenue of $38M, up from $36.8M YoY. Despite a 3.6% decrease in gross profit, operating income increased by 122% to $1.5M. The company also reported a net income of $1.5M, compared to a net loss of $9,000 in the same period last year. The company has entered into a strategic partnership with China Huanqiu Contracting & Engineering Co., Ltd. and is serving as the chief executive entity of the Belt and Road Enterprise Development Association.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 12:12 pm

DERM

Journey Medical Corporation has entered an exclusive license agreement with Maruho Co., Ltd. for Qbrexza in South Korea and other Asian nations. The company will receive a $19M upfront payment and is eligible for certain milestones totaling up to $45M.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 12:09 pm

LDOS

Leidos (NYSE:LDOS) has completed the full cloud deployment of the Department of Defense's Automated Biometrics Information System (ABIS). This is a significant step towards securing fully automated biometrics capabilities in the cloud, promising increased system availability and performance globally. The work was performed under the Biometrics Enabling Capability, Increment One (BEC-1) contract. The deployment has improved the efficiency of the Biometrically Enabled Watch List Dissemination Management Functionality (BDMF), reducing the time required to process biometric data from days to hours.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 12:09 pm

GE

GE HealthCare and Mass General Brigham have co-developed an AI algorithm to predict missed care opportunities (MCO) and late arrivals, aiming to increase operational effectiveness and productivity. The algorithm, part of the Radiology Operations Module (ROM), was able to predict MCOs with up to 96% accuracy in preliminary tests. The collaboration is part of a 10-year commitment signed in 2017 to explore the use of AI in healthcare.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 12:08 pm

AMRX

Amneal Pharmaceuticals has received approval for its first product, Sevelamer Carbonate, in China and expects to launch it soon. The company also plans to launch Oseltamivir Phosphate in China this year, pending approval. Amneal has six more products under review in China and plans to register more over time. Since 2019, Amneal has been collaborating with Fosun Pharmaceuticals to bring key therapies to market in China.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 12:05 pm

CDTX

JNJ

Cidara Therapeutics announced that Janssen has elected to proceed under its license agreement relating to novel drug-Fc conjugates targeting influenza. Cidara will receive a $7M milestone payment and is eligible for an additional $685M.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 12:03 pm

CRM

Genesys and Salesforce (NYSE:CRM) have announced a strategic collaboration to launch a unified AI-powered customer experience and relationship management solution. The solution, called CX Cloud, integrates Genesys Cloud CX and Salesforce Service Cloud.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 12:01 pm

ACB

Aurora Cannabis Inc. (NASDAQ:ACB) has announced a partnership with Brazilian company Herbarium to expand its hemp-derived CBD portfolio into Brazil. The company will launch its full-spectrum, single-source 3% CBD oil under the Herbarium brand, making it available to patients across Brazil under the direction of medical doctors.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:51 am

BRKR

DFLI

Dragonfly Energy has highlighted the use of Bruker Corporation's battery research equipment in its operations. The equipment is instrumental in Dragonfly's research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:47 am

ERNA

LCTX

Lineage Cell Therapeutics Inc (LCTX) has started development activities under its exclusive license agreement with Eterna Therapeutics Inc (ERNA) to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line. This is part of a strategic collaboration announced in February 2023, where Eterna is developing engineered hypoimmune iPSC lines that Lineage will evaluate for differentiation into cell transplant product candidates for central nervous system diseases and other neurology indications. Lineage will make payments to Eterna in connection with Eterna’s successful development and delivery of certain materials.

Portfolio Pulse from Vandana Singh

September 06, 2023 | 11:40 am